TRAIL, Fas Ligand, TNF and TLR3 in Cancer
This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of canc
- PDF / 8,634,459 Bytes
- 320 Pages / 439.43 x 683.15 pts Page_size
- 32 Downloads / 155 Views
Olivier Micheau Editor
TRAIL, Fas Ligand, TNF and TLR3 in Cancer
Resistance to Targeted Anti-Cancer Therapeutics Volume 12
Series Editor: Benjamin Bonavida
More information about this series at http://www.springer.com/series/11727
Olivier Micheau Editor
TRAIL, Fas Ligand, TNF and TLR3 in Cancer
Editor Olivier Micheau INSERM, LNC UMR 1231 Dijon, France
ISSN 2196-5501 ISSN 2196-551X (electronic) Resistance to Targeted Anti-Cancer Therapeutics ISBN 978-3-319-56804-1 ISBN 978-3-319-56805-8 (eBook) DOI 10.1007/978-3-319-56805-8 Library of Congress Control Number: 2017943866 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Receptors and ligands of the TNF superfamily, with the exception of a few members, are transmembrane glycoproteins. They display pleiotropic functions. Several receptors of the family are able to induce apoptosis or cell death. Their cognate ligands are instrumental to immune cells, allowing eradication of unwanted, virally infected or transformed cells. Among these, TRAIL has early on attracted a major interest in oncology, owing to its ability to selectively trigger tumor cell killing while sparing normal cells. TRAIL induces cell death through binding to its two agonist receptors, namely TRAIL-R1 and TRAIL-R2. Its use in the clinic, however, despite clear clinical evidence of antitumoral activity, has remained limited due to a plethora of molecular mechanisms leading to cell resistance as well as to our poor understanding of the biological function and regulation of its receptors. Therapeutic strategies or options to exploit TRAIL or its derivatives in onco
Data Loading...
